As a project manager, the responsibility is to keep long development timelines and large budgets under control by proactively managing regulatory uncertainty, particularly for Class II and Class III medical devices. A PM should never assume a best-case scenario timeline and instead plan for multiple regulatory outcomes. This requires flexibility in scheduling and anticipation of FDA questions, extended review cycles, and potential changes to animal or human clinical trials. Risk can be reduced by front-loading regulatory interactions with the FDA and conducting thorough verification and validation testing before initiating animal or clinical studies. These steps are especially important given the inherently unpredictable nature of such trials, which may produce unexpected results that require additional analysis or protocol changes. As a result, developing contingency plans and alternative courses of action is essential for minimizing delays and managing additional costs. 
Then in the eventual case that the delays or cost increases do inevitably occur, the PM must manage trade offs to realign with what the company needs. These trade offs can come in the form of a reduction to narrowing scopes to save the length of the timeline, or reducing potential features on the projects scope to save time during an FDA review. Another trade off that can be used depending on the budget to save time is to increase resources, or conduct parallel testing to reduce time needed on the research stage, which allows for FDA reviews to occur quicker, reducing the timeline and even freeing up more time to make changes to adhere to any concerns the FDA may have. Ultimately, all of which the PM has to take into account at any time during the project. If anyone has any other trade offs that could be included to resolve project issues, I would also like to hear them!

For Class II and Class III medical devices long timelines and high costs are almost always inevitable. Because of this, one of the most important roles of a project manager is to maintain control over the budget and timeline. One way a project manager can ensure a project follows the intended schedule and budget is to create a Design and Development Plan (DDP) early on in the project. In the project plan, they should include all steps of the design control process, such as design inputs, risk management, verification and validation, and animal and clinical trials. The plan should also incorporate regular design reviews so that issues can be identified early before they hinder the project timeline and cause increased expenses. Another thing a project manager can do to combat unpredictability is build extra time in the schedule from the start of a project. Doing so will help potential delays be less detrimental to a project. If delays do occur, and the buffer time included in the schedule isn’t sufficient, the project manager must look for tradeoffs to get the project back up to speed, without compromising regulatory compliance. Some tradeoffs a project manager may need to negotiate are potentially delaying the product launch date or reallocating company resources from projects with less priority.

I think you make a good point about planning for uncertainty, since it is almost never possible for a best-case timeline for sure. This is especially applicable for Class II and III devices. One thing I would add is the importance of early alignment between regulatory and business sectors. Even if there are contingency plans, delays in animal trials or clinical trials can have effects downstream where commercialization plans can be delayed, reimbursement will be delayed, and competitiveness of the company will be altered. For this, the PM must properly manage the schedule and help leadership understand how regulatory delays can become a risk to business. 

Something else that PMs have to manage is deciding when to engage the FDA and how much data should be collected before FDA interaction. Early FDA engagement can reduce uncertainty, but it can also lead to more requirements that would increase project load and scope, as well as cost. Balancing communication with the FDA while making sure resources are not overcommitted is critical for the role of PM. Decisions around trial design, like expanding endpoints or populations, can improve regulation but also add time. 

I think making sure expectations are managed is a good tool as well. PMs have to reset timelines often, so it is important that the team does not think regulatory delays are project failures. The teams should think that delays are a normal part of the project and process for devices with high risk. 

I want to know how others have seen this handled in practice. How do PMs balance pressure from leadership while also moving quickly and reliably with FDA timelines? How do you think AI can be integrated into PM management tasks in order to make these balancing changes more efficient? Where do we draw the line? Do you think engaging the FDA earlier saves time overall, or does it increase project complexity?

When it come to being a PM and working on and helping with the timeline for Class II and Class III device can be especially challenging as it is always changing due to feedback from the FDA. As a PM you should never assume the project timeline will work out in the best case senario as it can lead to false data and hope to be instilled which can be a bad thing. Most of the time the FDA will reject the first application for these devices and can lead to roadblock that will need to be addressed before it can be done again. As the PM there need to be a plan in place for the timeline but also needs to be the ability to be able to make changes and adjust to roadblock that occur in the plan itself and the timeline. A lot of the problem typically occur during the animal testing phase and clinical trial if they are needed. These process take the most time and most of the problems typically occur during this process and by having a more flexible timeline helps to mitigate a setback and can allow for project to keep moving even though there is problem. By doing so it allow the whole project to not go out the door and the timeline to stay consistent and moving forwards as best a possible.